Iconic Therapeutics

16 articles about Iconic Therapeutics

• 

  Zymeworks Mulls $733 Million Bid from All Blue Capital

  4/29/2022

  Zymeworks received an unsolicited, non-binding acquisition offer from global investment firm All Blue Capital. All Blue is offering $10.50 per share for a total of $773 million in cash.

• Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor

  1/6/2022

  Exelixis, Inc. (Nasdaq: EXEL) and Iconic Therapeutics, Inc. (Iconic) today announced that the companies have amended the terms of their May 2019 exclusive option and license agreement for XB002 (formerly ICON-2), a next-generation tissue factor (TF)-targeting antibody-drug conjugate (ADC).

• Dirk Sauer, Ph.D. Joins Iconic Therapeutics' Board of Directors

  4/20/2021

  Iconic Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to translating an understanding of Tissue Factor (TF) biology to new therapeutics for cancer, retinal disease and inflammation, today announced that Dirk Sauer, Ph.D., former Novartis Pharma AG’s Global Development Unit Head, Ophthalmology, has joined the company

• Iconic Therapeutics Signs Ophthalmology Option Agreement

  8/22/2019

  Upfront payment and equity investment made to secure option on antibody for ophthalmology

• Exelixis and Iconic Therapeutics Enter into Exclusive Option and License Agreement for Novel Antibody-Drug Conjugate Program

  5/16/2019

  ICON-2 program targets Tissue Factor (TF) with potential broad impact in oncology

• Zymeworks Enters its First ZymeLink™ Antibody-Drug Conjugate Platform Licensing Agreement with Iconic Therapeutics

  5/14/2019

  Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that it has entered into a licensing agreement that grants Iconic Therapeutics, Inc. (Iconic) non-exclusive rights to Zymeworks’ proprietary ZymeLink™ antibody-drug conjugate (ADC) platform for the development of its ICON-2 Tissue Factor ADC for cancer.

• Iconic Therapeutics Initiates Second Phase 2 Study of ICON-1 in Patients With Neovascular (wet) AMD

  5/16/2018

  DECO Study to Explore Dosing Regimen with Higher ICON-1 Dose

• Iconic Therapeutics, Inc. Appoints Brandon Smith Chief Operating Officer

  8/22/2017

• Iconic Therapeutics, Inc. Appoints Julia P. Gregory To Board Of Directors

  4/6/2017

• Iconic Therapeutics, Inc. To Present Phase IIa EMERGE Trial Results At Miami Meeting

  2/9/2017

• Iconic Therapeutics, Inc. Announces Final Close Of Series C Financing With Additional $10 Million Investment

  8/9/2016

• K. Peter Hirth, PhD, Joins Iconic Therapeutics, Inc. As Board Member And Senior Scientific Advisor

  5/12/2015

• Iconic Therapeutics, Inc. Nabs $20 Million For Wet AMD Program

  4/16/2014

• Iconic Therapeutics, Inc. Announces Phase 1 Wet AMD Study Results

  11/9/2012

• Laureate Pharma, Inc. and Iconic Therapeutics, Inc. Announce Production of Clinical Material

  1/7/2010

• Laureate Pharma, Inc. And Iconic Therapeutics, Inc. Announce Immunoprotein Manufacturing Agreement

  5/10/2006